LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") .  Such investors are advised to contact Danielle Peyton at ...

February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...

Plaintiffs' lawyers behind a pending $2.8 billion class action antitrust settlement with Blue Cross Blue Shield on Sunday ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

A new class schedule for community education courses at Pennsylvania Highlands Community College has been set to start in March. The 28 non-credit classes will be offered in Career training, arts and ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31, 2024, ...

Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. securities between November 2, ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.